Designing Allosteric Protein Switches by In Vivo Directed Evolution and Computational Inference
DaVinci-Switches aims to revolutionize switchable protein engineering by combining synthetic biology and machine learning to create light- and drug-inducible proteins for regenerative medicine applications.
Projectdetails
Introduction
Proteins are molecular machines that drive all major functions in cells. Controlling the activity of proteins in real time via light or chemicals is a central goal in synthetic biology. The design of switchable proteins, in particular single-chain, allosteric variants, however, is a challenging engineering problem thus far mostly addressed by trial-and-error.
Project Overview
DaVinci-Switches takes a radically new, data-driven perspective to fundamentally advance our understanding of protein allostery and accelerate and eventually rationalize the engineering of switchable proteins by interfacing synthetic biology with machine learning.
Methodology
-
Design by Directed Evolution
We will establish a 'design by directed evolution' approach to create switchable proteins through receptor and effector fusion followed by phage-assisted in vivo directed evolution using synthetic gene circuits for selection. -
Monitoring Evolutionary Process
We will apply this novel pipeline to a diverse set of effector proteins and monitor the evolutionary process by next-generation sequencing (Objective 1). -
Computational Analysis
In parallel, we will perform an in-depth computational analysis of domain insertions within the natural protein repertoire. The combined, rich datasets will be used to train machine learning models to infer sequence patterns predictive of domain insertion tolerance and allosteric coupling between receptor-effector pairs (Objective 2).
Application
Finally, we will employ this unique model to design light- and drug-inducible variants of the Yamanaka cell reprogramming factors. These will provide the foundation of an Adeno-associated virus-based platform for cyclic, partial in vivo reprogramming of somatic cells with enormous potential for regenerative medicine, which will be evaluated in a murine model of drug-induced liver injury (Objective 3).
Conclusion
DaVinci-Switches harnesses our key competences in protein engineering, synthetic biology, and computation to reveal fundamental principles of allostery and enable transformative advances in the design of switchable proteins for research and medicine.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.619.687 |
Totale projectbegroting | € 1.619.687 |
Tijdlijn
Startdatum | 1-9-2022 |
Einddatum | 31-8-2027 |
Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- RUPRECHT-KARLS-UNIVERSITAET HEIDELBERGpenvoerder
- TECHNISCHE UNIVERSITAT DARMSTADT
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Protein function regulation through inserts for response to biological, chemical and physical signalsThis project aims to develop a modular platform for engineering proteins to sense and respond to diverse signals, enhancing their functionality for innovative biomedical applications. | ERC Advanced... | € 2.500.000 | 2024 | Details |
Engineered control of cellular circuitsDeveloping light-controlled proteins to study spatiotemporal dynamics of signaling in active neuron subpopulations during learning, aiming to inform therapies for brain disorders. | ERC Starting... | € 1.494.669 | 2023 | Details |
DNA-encoded REconfigurable and Active MatterThe project aims to develop DNA-encoded dynamic principles to create adaptive synthetic materials with life-like characteristics and multifunctional capabilities through innovative self-assembly and genetic programming. | ERC Advanced... | € 2.496.750 | 2023 | Details |
A general approach for the design of covalent protein proximity inducersThis project aims to expand biochemical perturbations using CoLDR chemistry to create small molecules that activate enzymes, modify PTMs, and control protein interactions for therapeutic applications. | ERC Consolid... | € 1.998.744 | 2024 | Details |
CTP-dependent molecular switches: an emerging new principle in cellular regulationC SWITCH aims to explore the diverse roles of CTP-dependent C-switch proteins in cellular regulation and their potential as novel antibacterial targets to combat antibiotic resistance. | ERC Advanced... | € 2.082.419 | 2023 | Details |
Protein function regulation through inserts for response to biological, chemical and physical signals
This project aims to develop a modular platform for engineering proteins to sense and respond to diverse signals, enhancing their functionality for innovative biomedical applications.
Engineered control of cellular circuits
Developing light-controlled proteins to study spatiotemporal dynamics of signaling in active neuron subpopulations during learning, aiming to inform therapies for brain disorders.
DNA-encoded REconfigurable and Active Matter
The project aims to develop DNA-encoded dynamic principles to create adaptive synthetic materials with life-like characteristics and multifunctional capabilities through innovative self-assembly and genetic programming.
A general approach for the design of covalent protein proximity inducers
This project aims to expand biochemical perturbations using CoLDR chemistry to create small molecules that activate enzymes, modify PTMs, and control protein interactions for therapeutic applications.
CTP-dependent molecular switches: an emerging new principle in cellular regulation
C SWITCH aims to explore the diverse roles of CTP-dependent C-switch proteins in cellular regulation and their potential as novel antibacterial targets to combat antibiotic resistance.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Bioorthogonal Implantable Iontronic Switch to Temporally Control the Local Release of ChemotherapeuticsThe project aims to develop an implantable bioSWITCH for on-demand drug delivery to tumors, enhancing treatment efficacy and survival rates in pancreatic cancer. | EIC Pathfinder | € 4.420.511 | 2023 | Details |
Bioorthogonal Implantable Iontronic Switch to Temporally Control the Local Release of Chemotherapeutics
The project aims to develop an implantable bioSWITCH for on-demand drug delivery to tumors, enhancing treatment efficacy and survival rates in pancreatic cancer.